Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Nintedanib

Brand: Ofev®
NICE TA: 379
Indication: Treating idiopathic pulmonary fibrosis (NICE TA379)
Disease category: Malignant disease and immunosuppression
Commissioning responsibility: NHS England
PbR excluded: Yes

Background

Nintedanib is recommended as an option for treating idiopathic pulmonary fibrosis, only if:
• the person has a forced vital capacity (FVC) between 50% and 80% of predicted
• the company provides nintedanib with the discount agreed in the patient access scheme and
• treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of 10% or more) in any 12-month period.
People whose treatment with nintedanib is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

Recommendation

LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA379 - Nintedanib for treating idiopathic pulmonary fibrosis

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red